NEW CEO AND CHAIRMAN OF THE BOARD IN SCN

(NGM:SCN)

On January 30, 2009, the Board of Scandinavian Clinical Nutrition AB (SCN) accepted Carsten Waern’s resignation from his assignment as CEO, and appointed Ulf Söderberg as new acting CEO. Board Member Jörn Erik Aas takes over as Chairman of the Board.

Carsten Waern resigns from his assignment as CEO, but remains an active Board Member of the company.

Ulf Söderberg is one of the founders of SCN, and has previously been both CEO and Chairman of the Board of the company. He has extensive experience from the health and nutrition industry, and will start his new assignment with immediate effect.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board, jea@scnutrition.com, +47 924 99 360

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).For more information, please visit www.scnutrition.coABm.